Giglio Rosa, Milan Serena, Inferrera Leandro, Tognetto Daniele, D'Esposito Fabiana, Visalli Federico, Gagliano Caterina, Zeppieri Marco
Department of Medicine, Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy.
Imperial College Ophthalmic Research Group (ICORG) Unit, Imperial College, 153-173 Marylebone Rd, London NW1 5QH, UK.
Nutrients. 2025 May 30;17(11):1885. doi: 10.3390/nu17111885.
Cataract formation remains a significant cause of global visual impairment. Increasing attention has been directed toward antioxidant-based interventions as potential non-surgical strategies to delay or prevent cataractogenesis, particularly in the age-related and diabetic contexts. This review summarizes recent preclinical evidence on nutritional antioxidants for the prevention of age-related and diabetic cataracts. Agents such as trimetazidine, Moringa oleifera stem extract, ginsenoside Rg1, lanosterol nanoparticles, β-casomorphin-7, and cerium oxide-based nanotherapies have been shown to mitigate oxidative damage, modulate redox signaling pathways, and preserve lens clarity. Advances in drug delivery, including topical formulations, nanoparticle carriers, and intravitreal injections, have been proposed to overcome the anatomical and pharmacokinetic barriers associated with the avascular lens. The new data support ongoing translational research to maximize the clinical use of antioxidants and highlight their therapeutic potential in the prevention of age-related and diabetic cataracts.
白内障的形成仍然是全球视力损害的一个重要原因。越来越多的关注集中在基于抗氧化剂的干预措施上,将其作为延缓或预防白内障发生的潜在非手术策略,特别是在年龄相关性和糖尿病性白内障方面。本综述总结了近期关于营养抗氧化剂预防年龄相关性和糖尿病性白内障的临床前证据。曲美他嗪、辣木茎提取物、人参皂苷Rg1、羊毛甾醇纳米颗粒、β-酪蛋白吗啡-7和基于氧化铈的纳米疗法等药物已被证明可减轻氧化损伤、调节氧化还原信号通路并保持晶状体透明度。为克服与无血管晶状体相关的解剖学和药代动力学障碍,人们提出了药物递送方面的进展,包括局部制剂、纳米颗粒载体和玻璃体内注射。这些新数据支持正在进行的转化研究,以最大限度地将抗氧化剂应用于临床,并突出其在预防年龄相关性和糖尿病性白内障方面的治疗潜力。